Using the Khorana risk score to predict venous thromboembolism and overall survival in a cohort of Hispanic patients with solid malignancies.
Hispanic
mortality
neoplasms
prognosis
venous thromboembolism
Journal
Ecancermedicalscience
ISSN: 1754-6605
Titre abrégé: Ecancermedicalscience
Pays: England
ID NLM: 101392236
Informations de publication
Date de publication:
2022
2022
Historique:
received:
28
06
2022
entrez:
23
2
2023
pubmed:
24
2
2023
medline:
24
2
2023
Statut:
epublish
Résumé
The Khorana risk score (KRS) for prognosis of venous thromboembolism (VTE) has been rarely explored in Hispanic populations. To determine the value of the KRS for prediction of VTE and overall survival (OS) among Hispanic individuals with cancer. We retrospectively evaluated all outpatients with newly diagnosed solid tumours receiving systemic chemotherapy in Hospital San Juan Dios, San José, Costa Rica, from January to December 2021. The 6-month cumulative VTE incidence according to the KRS categories was estimated using the Fine & Gray competing risk model. A Kaplan-Meier analysis was used to compare OS among KRS categories. The Cox regression analysis was performed to calculate the hazard ratio (HR) and its corresponding 95% confidence interval (CI). The receiver operating characteristic (ROC) analysis was performed to identify the optimal cutoff value to predict VTE during follow-up. A total of 708 patients were included in the analysis. After a median follow-up of 8.13 months, the cumulative incidence of VTE at 6 months was 1.56% (95% CI: 0.83%-6.82%), 4.83% (95% CI: 2.81%-7.66%) and 8.84% (95% CI: 4.30%-15.42%) for low-, intermediate- and high-risk Khorana score categories, respectively (Gray's The KRS is a valid tool to predict VTE and mortality in a cohort of Hispanic outpatients with newly diagnosed solid tumours.
Sections du résumé
Background
UNASSIGNED
The Khorana risk score (KRS) for prognosis of venous thromboembolism (VTE) has been rarely explored in Hispanic populations.
Objective
UNASSIGNED
To determine the value of the KRS for prediction of VTE and overall survival (OS) among Hispanic individuals with cancer.
Methods
UNASSIGNED
We retrospectively evaluated all outpatients with newly diagnosed solid tumours receiving systemic chemotherapy in Hospital San Juan Dios, San José, Costa Rica, from January to December 2021. The 6-month cumulative VTE incidence according to the KRS categories was estimated using the Fine & Gray competing risk model. A Kaplan-Meier analysis was used to compare OS among KRS categories. The Cox regression analysis was performed to calculate the hazard ratio (HR) and its corresponding 95% confidence interval (CI). The receiver operating characteristic (ROC) analysis was performed to identify the optimal cutoff value to predict VTE during follow-up.
Results
UNASSIGNED
A total of 708 patients were included in the analysis. After a median follow-up of 8.13 months, the cumulative incidence of VTE at 6 months was 1.56% (95% CI: 0.83%-6.82%), 4.83% (95% CI: 2.81%-7.66%) and 8.84% (95% CI: 4.30%-15.42%) for low-, intermediate- and high-risk Khorana score categories, respectively (Gray's
Conclusions
UNASSIGNED
The KRS is a valid tool to predict VTE and mortality in a cohort of Hispanic outpatients with newly diagnosed solid tumours.
Identifiants
pubmed: 36819798
doi: 10.3332/ecancer.2022.1470
pii: can-16-1470
pmc: PMC9934874
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1470Informations de copyright
© the authors; licensee ecancermedicalscience.
Déclaration de conflit d'intérêts
None to declare.
Références
Thromb Haemost. 2022 May;122(5):662-665
pubmed: 34670288
Blood. 2008 May 15;111(10):4902-7
pubmed: 18216292
Thromb Res. 2010 Jun;125(6):490-3
pubmed: 20097409
Cureus. 2020 Apr 29;12(4):e7883
pubmed: 32489737
J Thromb Haemost. 2018 Jun;16(6):1069-1077
pubmed: 29573330
Thromb Res. 2017 Feb;150:30-32
pubmed: 28002757
Cancer. 2007 Nov 15;110(10):2339-46
pubmed: 17918266
J Thromb Haemost. 2020 Aug;18(8):1940-1951
pubmed: 32336010
Lancet Haematol. 2018 Jul;5(7):e289-e298
pubmed: 29885940
Blood Adv. 2022 May 24;6(10):3167-3177
pubmed: 35171995
Support Care Cancer. 2021 Mar;29(3):1699-1709
pubmed: 32776163
J Clin Oncol. 2020 Feb 10;38(5):496-520
pubmed: 31381464
Blood Adv. 2021 Feb 23;5(4):927-974
pubmed: 33570602
Blood Adv. 2022 May 24;6(10):2967-2976
pubmed: 35045569
J Thromb Haemost. 2016 Sep;14(9):1773-8
pubmed: 27273134
Blood. 2021 Apr 8;137(14):1959-1969
pubmed: 33171494
Oncologist. 2021 Jan;26(1):e2-e7
pubmed: 33274815
Haematologica. 2019 Jun;104(6):1277-1287
pubmed: 30606788
Clin Appl Thromb Hemost. 2018 Nov;24(8):1347-1351
pubmed: 29806470
Sci Rep. 2020 Oct 28;10(1):18516
pubmed: 33116272
Arch Intern Med. 2006 Feb 27;166(4):458-64
pubmed: 16505267
Contemp Clin Trials. 2011 Nov;32(6):829-33
pubmed: 21777700
Blood. 2013 Sep 5;122(10):1712-23
pubmed: 23908465
Haematologica. 2017 Sep;102(9):1494-1501
pubmed: 28550192
Clin Transl Oncol. 2014 Oct;16(10):927-30
pubmed: 24643701
J Thromb Haemost. 2015 Mar;13(3):390-7
pubmed: 25529107
Sci Rep. 2021 Sep 14;11(1):18200
pubmed: 34521927